BrainsWay is the most broadly FDA-cleared deep TMS company, with distinct clearances across MDD, OCD, smoking cessation, and anxiety, plus a recent adolescent expansion, giving it the widest approved indication set of any TMS system on the market. As a publicly traded company with established clinical reimbursement pathways, it is best understood as an incumbent platform in non-invasive psychiatric neuromodulation rather than an emerging startup.